Healthcare
Demant A/S(WILYY)
Live Price
Offline$19.25
+0.00% today
1Y Change
-9.24%
Window
Jun 23, 2025 β Jun 15, 2026
- Market Cap
- $44.88B
- Revenue Growth
- +2.5%
- EPS Growth
- -35.5%
- Dividend Yield
- 0.0%
Coverage: 246 bars Β· Jun 23, 2025 β Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Demant A/S (WILYY) is a Healthcare stock with a market cap of $44.88B and listed on OTC. The stock last traded around $19.25 and down 9.2% across the available one-year price window (Jun 23, 2025 β Jun 15, 2026). Baseline metrics include revenue growth of +2.5%, EPS growth of -35.5%, a dividend yield of 0.0%. What stands out right now is revenue +2.5%, EPS -35.5%, free cash flow -3.8% with operating margin 17.6% and ROIC 9.2%. Valuation is more restrained than many high-expectation growth names at P/E 29.0 and price/sales 1.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines WILYY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+2.5% vs +7.6% peer median
Operating Margin
Near sector median
+17.6% vs +19.4% peer median
P/E
Below sector median
29.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 27, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +2.5% and EPS is at -35.5%, with operating margin around 17.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.4% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 27, 2026 | β | -2.6% | +0.2% | β |
2025 Aug 12, 2025 | β | -1.5% | -1.5% | -0.1% |
2025 May 29, 2025 | β | +0.0% | +0.0% | -5.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WILYY
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
WILYY Max Drawdown
-36.88%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for WILYY and SPY.
Company Overview
Demant A/S
Other OTC
Demant A/S, a hearing healthcare and audio technology company, develops, manufactures, and sells products and equipment to enhance people's hearing in Europe, North America, the Pacific, Asia, and internationally. It operates in two segments, Hearing Healthcare and Communications. The Hearing Healthcare segment offers hearing implants and aids, hearing care, and diagnostic products. The Communications segment provides headsets for collaborative work and gaming markets under the EPOS brand name. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in SmΓΈrum, Denmark.
- Leadership
- SΓΈren Nielsen
- IPO Date
- Jun 24, 2011
- Employees
- 19.9k
- Street Address
- Kongebakken 9
- Mailing
- SmΓΈrum, 2765
- Region
- SmΓΈrum, DK
- Reporting Currency
- USD
- Investor Line
- 45 39 17 73 00
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 29.0
- EV/EBITDA
- 13.1
- Price/Sales
- 1.9
- Price/Book
- 4.6
Growth
- Revenue
- +2.5%
- EPS
- -35.5%
- Free Cash Flow
- -3.8%
Profitability
- Gross Margin
- 69.9%
- Operating Margin
- 17.6%
- Net Margin
- 6.7%
- ROE
- 16.1%
- ROIC
- 9.2%
Balance Sheet
- Debt/Equity
- 2.39
- Current Ratio
- 1.33
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.